Evidence map›Paper›PMID 42448890›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II.

Etienne Aumont, Lydia Trudel, Brandon J Hall, Tevy Chan, Seyyed Ali Hosseini, Arthur C Macedo, Joseph Therriault, Jaime Fernandez Arias, Aurélie Lebrun, Delphine Oliva-Lopez and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Etienne AumontMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.ORCID http://orcid.org/0000-0002-8997-7090
Lydia TrudelMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Brandon J HallMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Tevy ChanMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Seyyed Ali HosseiniMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Arthur C MacedoMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Joseph TherriaultMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Jaime Fernandez AriasMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Aurélie LebrunMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Delphine Oliva-LopezMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Nesrine RahmouniMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Gleb BezginMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Jenna StevensonMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Stijn ServaesMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Vladimir FonovMontreal Neurological Institute, McGill University, Montréal, QC, H3A 2B4, Canada.
Chris HsiaoMontreal Neurological Institute, McGill University, Montréal, QC, H3A 2B4, Canada.
Robert HopewellMontreal Neurological Institute, McGill University, Montréal, QC, H3A 2B4, Canada.
Paolo VitaliMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Jesse KlostranecMontreal Neurological Institute, McGill University, Montréal, QC, H3A 2B4, Canada.
Maxime MontembeaultMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Yasser Iturria-MedinaMontreal Neurological Institute, McGill University, Montréal, QC, H3A 2B4, Canada.
Suzanne L BakerLawrence Berkeley National Laboratory, University of California, Berkeley, CA, USA.
Serge GauthierMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada.
Pedro Rosa-NetoMcGill University Research Centre for Studies in Aging, McGill University, 6825 Boulevard LaSalle, Verdun, Québec, H4H 1R3, Canada. etienne.aumont@mcgill.ca.

Funding

Alzheimer's Association NIRG-12-92090Alzheimer's Association NIRP-12-259245Consortium canadien en neurodégénérescence associée au vieillissement MOP-11-51-31Fondation Brain Canada 33397Fondation Brain Canada CFI Project 34874Fonds de Recherche du Québec - Santé 2020-VICO-279314Fonds de Recherche du Québec - Santé 2024 VICO-356138Institute of Aging 152985Institute of Aging 159815Institute of Aging 162303Institute of Aging Postdoctoral fellowship
6 · The paper itself

Abstract

purposeTau-PET enables in-vivo staging of Alzheimer disease (AD) pathology, including early Braak stage II involvement of the hippocampus. Conventional whole-hippocampus definitions combine heterogeneous subfields and are susceptible to off-target signal that varies across tracers, limiting sensitivity, specificity, and longitudinal interpretability of early tau accumulation.

methodsCross-sectional and longitudinal analyses were conducted in the TRIAD (N = 456) and the ADNI (N = 497) observational cohorts with tau-PET with [

resultsSpatial analyses localised early hippocampal tau-PET signal predominantly to the anterior CA1. Whole-hippocampus measures were more frequently influenced by off-target signal consistent with choroid plexus contamination. Participants classified as CA1-based Braak stage II showed higher amyloid-PET burden, more consistent tau accumulation in the Braak stage III region, and more stable longitudinal progression. CA1-based staging yielded fewer discordant classifications and fewer stage regressions at follow-up.

conclusionCA1-specific tau-PET quantification improves biological plausibility and longitudinal consistency of Braak stage II classification by targeting the hippocampal subfield most vulnerable to early tau pathology and mitigating off-target contamination. CA1-based Braak stage II participants showed greater coherence with the biological framework of AD than those staged using the whole hippocampus. Applicable to available PET resolution, this approach may enhance characterisation of early AD and support participant selection in trials targeting preclinical tau accumulation.

Indexed as

Alzheimer DiseaseCA1 Region, HippocampalHippocampusPositron-Emission Tomographytau ProteinsAgedAged, 80 and overCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaletau ProteinsAlzheimer’s diseaseBraak stagesHippocampusTau-PET

Identifiers

PMID42448890

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.